Literature DB >> 21792603

[Pathobiology of the microRNA system].

K Hussein1.   

Abstract

MicroRNAs are approximately 22 nucleotides short, non-protein-coding RNA molecules, which bind semi-complementary to mRNA and have an inhibitory effect on protein expression. Aberrant microRNA expression is part of the molecular pathological damage in several degenerative, inflammatory and neoplastic diseases and deregulation can also be virus-associated. Apart from intracellular regulatory functions, microRNA in platelets and exosomes or bound to extracellular protein complexes can also circulate in the blood. Artificial microRNA analogues (small interference RNA/siRNA) and anti-microRNA (antagomir) are used in molecular pathological research of microRNA/mRNA interaction and it is thought that they will also be used as therapeutic agents in the future.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21792603     DOI: 10.1007/s00292-011-1469-4

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  45 in total

1.  Aberrant microRNA expression pattern in myelodysplastic bone marrow cells.

Authors:  Kais Hussein; Katharina Theophile; Guntram Büsche; Brigitte Schlegelberger; Gudrun Göhring; Hans Kreipe; Oliver Bock
Journal:  Leuk Res       Date:  2010-06-03       Impact factor: 3.156

2.  Secreted monocytic miR-150 enhances targeted endothelial cell migration.

Authors:  Yujing Zhang; Danqing Liu; Xi Chen; Jing Li; Limin Li; Zhen Bian; Fei Sun; Jiuwei Lu; Yuan Yin; Xing Cai; Qi Sun; Kehui Wang; Yi Ba; Qiang Wang; Dongjin Wang; Junwei Yang; Pingsheng Liu; Tao Xu; Qiao Yan; Junfeng Zhang; Ke Zen; Chen-Yu Zhang
Journal:  Mol Cell       Date:  2010-07-09       Impact factor: 17.970

Review 3.  MicroRNA-21: from cancer to cardiovascular disease.

Authors:  Virginija Jazbutyte; Thomas Thum
Journal:  Curr Drug Targets       Date:  2010-08       Impact factor: 3.465

4.  Down-regulation of hsa-miR-10a in chronic myeloid leukemia CD34+ cells increases USF2-mediated cell growth.

Authors:  Xabier Agirre; Antonio Jiménez-Velasco; Edurne San José-Enériz; Leire Garate; Eva Bandrés; Lucia Cordeu; Oscar Aparicio; Borja Saez; Germán Navarro; Amaia Vilas-Zornoza; Ignacio Pérez-Roger; Jesús García-Foncillas; Antonio Torres; Anabel Heiniger; María José Calasanz; Puri Fortes; José Román-Gómez; Felipe Prósper
Journal:  Mol Cancer Res       Date:  2008-12       Impact factor: 5.852

5.  Single nucleotide polymorphisms in miRNA binding sites and miRNA genes as breast/ovarian cancer risk modifiers in Jewish high-risk women.

Authors:  Tair Kontorovich; Asaf Levy; Michael Korostishevsky; Uri Nir; Eitan Friedman
Journal:  Int J Cancer       Date:  2010-08-01       Impact factor: 7.396

Review 6.  MicroRNA in lung cancer.

Authors:  P-Y Lin; S-L Yu; P-C Yang
Journal:  Br J Cancer       Date:  2010-09-21       Impact factor: 7.640

7.  MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma.

Authors:  Aaron J Schetter; Suet Yi Leung; Jane J Sohn; Krista A Zanetti; Elise D Bowman; Nozomu Yanaihara; Siu Tsan Yuen; Tsun Leung Chan; Dora L W Kwong; Gordon K H Au; Chang-Gong Liu; George A Calin; Carlo M Croce; Curtis C Harris
Journal:  JAMA       Date:  2008-01-30       Impact factor: 56.272

8.  Epigenetic inactivation of microRNA gene hsa-mir-9-1 in human breast cancer.

Authors:  U Lehmann; B Hasemeier; M Christgen; M Müller; D Römermann; F Länger; H Kreipe
Journal:  J Pathol       Date:  2008-01       Impact factor: 7.996

9.  Deep sequencing reveals novel microRNAs and regulation of microRNA expression during cell senescence.

Authors:  Joseph M Dhahbi; Hani Atamna; Dario Boffelli; Wendy Magis; Stephen R Spindler; David I K Martin
Journal:  PLoS One       Date:  2011-05-26       Impact factor: 3.240

10.  Myeloid cell differentiation arrest by miR-125b-1 in myelodysplastic syndrome and acute myeloid leukemia with the t(2;11)(p21;q23) translocation.

Authors:  Marina Bousquet; Cathy Quelen; Roberto Rosati; Véronique Mansat-De Mas; Roberta La Starza; Christian Bastard; Eric Lippert; Pascaline Talmant; Marina Lafage-Pochitaloff; Dominique Leroux; Carine Gervais; Franck Viguié; Jean-Luc Lai; Christine Terre; Berna Beverlo; Costantina Sambani; Anne Hagemeijer; Peter Marynen; Georges Delsol; Nicole Dastugue; Cristina Mecucci; Pierre Brousset
Journal:  J Exp Med       Date:  2008-10-20       Impact factor: 14.307

View more
  5 in total

1.  Increased megakaryocytic proliferation, pro-platelet deposition and expression of fibrosis-associated factors in children with chronic myeloid leukaemia with bone marrow fibrosis.

Authors:  K Hussein; A Stucki-Koch; G Göhring; H Kreipe; M Suttorp
Journal:  Leukemia       Date:  2017-02-27       Impact factor: 11.528

2.  MicroRNA expression in Epstein-Barr virus-associated post-transplant smooth muscle tumours is related to leiomyomatous phenotype.

Authors:  Danny Jonigk; Nicole Izykowski; Lavinia Maegel; Eileen Schormann; Britta Maecker-Kolhoff; Florian Laenger; Hans Kreipe; Kais Hussein
Journal:  Clin Sarcoma Res       Date:  2013-07-06

3.  Tumour angiogenesis in Epstein-Barr virus-associated post-transplant smooth muscle tumours.

Authors:  Danny Jonigk; Nicole Izykowski; Lavinia Maegel; Eileen Schormann; Britta Ludewig; Hans Kreipe; Kais Hussein
Journal:  Clin Sarcoma Res       Date:  2014-01-07

Review 4.  Circulating Cytokine Levels as Markers of Inflammation in Philadelphia Negative Myeloproliferative Neoplasms: Diagnostic and Prognostic Interest.

Authors:  Julie Mondet; Kais Hussein; Pascal Mossuz
Journal:  Mediators Inflamm       Date:  2015-10-07       Impact factor: 4.711

5.  Prognostic Value of microRNA-221/2 and 17-92 Families in Primary Glioblastoma Patients Treated with Postoperative Radiotherapy.

Authors:  Elena Schnabel; Maximilian Knoll; Christian Schwager; Rolf Warta; Andreas Mock; Benito Campos; Laila König; Christine Jungk; Wolfgang Wick; Andreas Unterberg; Jürgen Debus; Christel Herold-Mende; Amir Abdollahi
Journal:  Int J Mol Sci       Date:  2021-03-15       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.